(Q44704123)

5 December 2017

title

Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients (English)

1 reference

5 December 2017

1 reference

Ellmén J

1

1 reference

5 December 2017

Hakulinen P

series ordinal

2

1 reference

5 December 2017

Partanen A

series ordinal

3

1 reference

5 December 2017

Hayes DF

series ordinal

4

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

Breast Cancer Research and Treatment

5 December 2017

published in

1 reference

5 December 2017

volume

82

1 reference

5 December 2017

issue

2

1 reference

5 December 2017

page(s)

103-111

1 reference

https://scigraph.springernature.com/pub.10.1023/b:brea.0000003957.54851.11

5 December 2017

exact match

0 references

cites work

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Second cancers after adjuvant tamoxifen therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

Pharmacokinetics of toremifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Meeting highlights: international consensus panel on the treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Agonistic and antagonistic effects of antiestrogens in different target organs

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Risk of endometrial cancer after tamoxifen treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Tamoxifen in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

A simplified method for the quantitative determination of testosterone-estradiol-binding globulin activity in human plasma

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Influence of toremifene on the endocrine regulation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000003957.54851.11

7 January 2021

10.1023/B:BREA.0000003957.54851.11

Identifiers

DOI

1 reference

Dimensions Publication ID

5 December 2017

1031852840

0 references

1 reference